Encorafenib Plus Binimetinib for BRAF-Mutated Metastatic Melanoma: 7-Year Follow-Up Data From the COLUMBUS Trial

The 7-year follow-up data for encorafenib/binimetinib showing that around 21% of patients remained progression-free supports BRAF/MEK inhibition as a later treatment option after immunotherapy failure, but doctors are reluctant to stop BRAF/MEK inhibitors given lack of data, even in those patients doing well long-term on the medications with minimal toxicity.

Related Content:

ESMO 2023: Expert Perspectives & Insights into the Testing and Treatment of MelanomaMelanoma & Skin CancerOncLive Peer Exchange®

Accelerated Approval Sought for RP1 Plus Nivolumab in Advanced Melanoma

Neoadjuvant Therapy NCCN Recommendations Take the Melanoma Field in a New Direction

Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice